{
  "event_id": "05b4eae94f93",
  "ticker": "SPRO",
  "company_name": "Spero Therapeutics",
  "drug_name": "Tebipenem HBr",
  "pdufa_date": "20181101",
  "approval_type": {
    "status": "found",
    "value": "nda",
    "source": "websearch:PIVOT-PO Phase 3 (NDA resubmitted Dec 2025)",
    "confidence": 0.9,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.623408",
    "error": null
  },
  "indication": {
    "status": "found",
    "value": "cUTI (oral carbapenem)",
    "source": "websearch:PIVOT-PO Phase 3 (NDA resubmitted Dec 2025)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.623409",
    "error": null
  },
  "generic_name": {
    "status": "not_searched",
    "value": null,
    "source": null,
    "confidence": 0.0,
    "evidence": [],
    "searched_sources": [],
    "last_searched": null,
    "error": null,
    "_reset_reason": "Was inferred from: comprehensive_mapping",
    "_reset_at": "2026-01-09T23:49:24.204703"
  },
  "therapeutic_area": {
    "status": "found",
    "value": "Infectious Disease",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-10T10:49:59.095478",
    "error": null
  },
  "phase": {
    "status": "found",
    "value": "Approved",
    "source": "derived_from_result",
    "confidence": 0.95,
    "tier": 1,
    "searched_sources": [
      "result_field"
    ],
    "last_searched": null,
    "error": null
  },
  "primary_endpoint_met": {
    "status": "found",
    "value": true,
    "source": "websearch:PIVOT-PO Phase 3 (NDA resubmitted Dec 2025)",
    "confidence": 0.85,
    "evidence": [
      "PIVOT-PO Phase 3 (NDA resubmitted Dec 2025)"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.623395",
    "error": null
  },
  "p_value": {
    "status": "not_applicable",
    "value": null,
    "source": "websearch:PIVOT-PO Phase 3 (NDA resubmitted Dec 2025)",
    "confidence": 0.9,
    "evidence": [
      "Single-arm or accelerated approval - no comparator p-value"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.623402",
    "error": null
  },
  "p_value_numeric": null,
  "effect_size": {
    "status": "found",
    "value": "Non-inferior to IV imipenem",
    "source": "websearch:PIVOT-PO Phase 3 (NDA resubmitted Dec 2025)",
    "confidence": 0.85,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-09T21:20:41.623404",
    "error": null
  },
  "safety_signal": {
    "status": "found",
    "value": false,
    "source": "default_for_approved",
    "confidence": 0.9,
    "tier": 1,
    "note": "No blocking safety signals at approval"
  },
  "phase3_study_names": [
    "A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)",
    "A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Multinational Study to Assess the Efficacy and Safety of Orally Administered Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenously Administered Imipenem-cilastatin in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)",
    "A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of SPR994 Following Single and Multiple Ascending Doses of SPR994 Administered Orally in Healthy Volunteers",
    "Phase 1 Study to Evaluate the Effect of Oral Administration of Tebipenem Pivoxil Hydrobromide on Normal Human Intestinal Microbiota in Healthy Volunteers"
  ],
  "nct_ids": [
    "NCT03788967",
    "NCT06059846",
    "NCT03395249",
    "NCT04376554"
  ],
  "enrollment": {
    "count": 1690,
    "type": "ACTUAL",
    "nct_id": "NCT06059846",
    "source": "clinicaltrials.gov",
    "fetched_at": "2026-01-10T17:30:45.933486"
  },
  "has_prior_crl": {
    "status": "found",
    "value": true,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "prior_crl_reason": null,
  "is_resubmission": {
    "status": "found",
    "value": 1,
    "source": "legacy_v12",
    "confidence": 0.75,
    "evidence": [],
    "searched_sources": [
      "legacy_v12"
    ],
    "last_searched": null,
    "error": null
  },
  "pai_passed": {
    "status": "found",
    "value": true,
    "source": "derived_from_approval",
    "confidence": 0.95,
    "tier": 1,
    "note": "Approved drugs must have passed PAI"
  },
  "warning_letter": {
    "status": "found",
    "value": false,
    "source": "inferred_from_approval",
    "confidence": 0.8,
    "tier": 2,
    "note": "Approved drugs unlikely to have blocking warning letters"
  },
  "result": "approved",
  "data_quality_score": 0.15,
  "collected_at": "2026-01-09T00:31:51.517554",
  "enriched_at": "2026-01-11T20:18:48.738910",
  "needs_manual_review": false,
  "review_reasons": [],
  "original_case_id": "4d47215ba44d",
  "fda_designations": {
    "breakthrough_therapy": false,
    "fast_track": true,
    "priority_review": true,
    "orphan_drug": true,
    "accelerated_approval": false
  },
  "mechanism_of_action": "Carbapenem antibiotic",
  "adcom_info": {
    "scheduled": false,
    "held": false,
    "outcome": null,
    "vote": null
  },
  "days_to_pdufa": -2627,
  "pdufa_status": "past",
  "risk_tier": "HIGH",
  "days_calculated_at": "2026-01-10T16:59:42.175911",
  "adcom_scheduled": {
    "value": false,
    "status": "confirmed_none",
    "source": "websearch_adcom",
    "confidence": 0.7,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:45:32.428476"
  },
  "adcom_vote_ratio": {
    "value": null,
    "status": "not_applicable",
    "source": "websearch_adcom",
    "confidence": 0.6,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch_adcom"
    ],
    "last_searched": "2026-01-11T08:45:32.428483"
  },
  "breakthrough_therapy": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:18:32.629251",
    "search_status": "CONFIRMED_NONE"
  },
  "orphan_drug": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:18:39.155421",
    "search_status": "CONFIRMED_NONE"
  },
  "priority_review": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.85,
    "tier": 2,
    "evidence": [
      "Spero Therapeutics Announces FDA Acceptance and Priority ..."
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:18:40.193674",
    "search_status": "FOUND"
  },
  "fast_track": {
    "value": true,
    "status": "found",
    "source": "websearch",
    "confidence": 0.75,
    "tier": 2,
    "evidence": [
      "Spero Therapeutics Announces Presentations on Tebipenem Hbr"
    ],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:18:43.944603",
    "search_status": "FOUND"
  },
  "accelerated_approval": {
    "value": null,
    "status": "not_found",
    "source": "websearch",
    "confidence": 0.0,
    "tier": 3,
    "evidence": [],
    "searched_sources": [
      "websearch"
    ],
    "last_searched": "2026-01-11T20:18:48.738890",
    "search_status": "CONFIRMED_NONE"
  }
}